Literature DB >> 6727272

Pharmacokinetics and absolute bioavailability of diltiazem in humans.

H R Ochs, M Knüchel.   

Abstract

Six healthy male volunteers received single doses of diltiazem hydrochloride on three occasions separated by at least 10 days. Modes of administration were: 10-minute intravenous infusion of a 20-mg dose; oral administration of 120 mg in solution form; and oral administration of 120 mg as two 60-mg sustained-release tablets. Diltiazem concentrations were measured by electron-capture gas chromatography in multiple plasma samples drawn during the 36 hours after dosage. Following intravenous administration, mean (+/- S.E.) pharmacokinetic variables were: elimination half-life, 11.2 (+/- 2.1) hours; volume of distribution, 11.1 (+/- 3.0) liters/kg; and total clearance, 11.5 (+/- 0.7) ml/min/kg. Oral diltiazem in solution form was rapidly absorbed, with peak plasma levels attained at 38 (+/- 6) minutes after the dose. Absolute systemic availability averaged 44% (+/- 4%). Oral administration of sustained-release tablets yielded, as predicted, slower absorption, with peak plasma concentrations attained at an average of 165 (+/- 22) minutes after dosage. Thus, oral diltiazem is incompletely bioavailable after oral administration, mainly because of first-pass hepatic extraction.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6727272     DOI: 10.1007/BF01716446

Source DB:  PubMed          Journal:  Klin Wochenschr        ISSN: 0023-2173


  11 in total

1.  Commentary: a physiological approach to hepatic drug clearance.

Authors:  G R Wilkinson; D G Shand
Journal:  Clin Pharmacol Ther       Date:  1975-10       Impact factor: 6.875

2.  Introduction: calcium channel blockers.

Authors:  E Braunwald
Journal:  Am J Cardiol       Date:  1980-12-01       Impact factor: 2.778

3.  Pharmacokinetics of diltiazem after intravenous and oral administration.

Authors:  P Hermann; S D Rodger; G Remones; J P Thenot; D R London; P L Morselli
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

Review 4.  Calcium antagonists.

Authors:  T T Zsotér
Journal:  Am Heart J       Date:  1980-06       Impact factor: 4.749

5.  Physiological disposition of verapamil in man.

Authors:  M Schomerus; B Spiegelhalder; B Stieren; M Eichelbaum
Journal:  Cardiovasc Res       Date:  1976-09       Impact factor: 10.787

Review 6.  Comparative pharmacology of calcium antagonists: nifedipine, verapamil and diltiazem.

Authors:  P D Henry
Journal:  Am J Cardiol       Date:  1980-12-01       Impact factor: 2.778

7.  Pharmacokinetic model of diltiazem.

Authors:  E U Kölle; H R Ochs; K O Vollmer
Journal:  Arzneimittelforschung       Date:  1983

8.  Nifedipine kinetics and bioavailability after single intravenous and oral doses in normal subjects.

Authors:  T S Foster; S R Hamann; V R Richards; P J Bryant; D A Graves; R G McAllister
Journal:  J Clin Pharmacol       Date:  1983-04       Impact factor: 3.126

9.  Diazepam absorption: effects of age, sex, and Billroth gastrectomy.

Authors:  H R Ochs; H Otten; D J Greenblatt; H J Dengler
Journal:  Dig Dis Sci       Date:  1982-03       Impact factor: 3.199

10.  Efficacy of diltiazem for control of symptoms of coronary arterial spasm.

Authors:  S J Rosenthal; R Ginsburg; I H Lamb; D S Baim; J S Schroeder
Journal:  Am J Cardiol       Date:  1980-12-01       Impact factor: 2.778

View more
  10 in total

1.  Continuous Intestinal Absorption Model Based on the Convection-Diffusion Equation.

Authors:  Swati Nagar; Richard C Korzekwa; Ken Korzekwa
Journal:  Mol Pharm       Date:  2017-07-31       Impact factor: 4.939

Review 2.  Diltiazem. A reappraisal of its pharmacological properties and therapeutic use.

Authors:  M M Buckley; S M Grant; K L Goa; D McTavish; E M Sorkin
Journal:  Drugs       Date:  1990-05       Impact factor: 9.546

3.  Prediction of drug distribution into human milk from physicochemical characteristics.

Authors:  H C Atkinson; E J Begg
Journal:  Clin Pharmacokinet       Date:  1990-02       Impact factor: 6.447

4.  Pharmacokinetics of slow-release diltiazem and its effect on atrioventricular conduction in healthy volunteers.

Authors:  A Gordin; P Pohto; S Sundberg; S Nykänen; H Haataja; P Männistö
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

5.  Dynamic, inter-subunit interactions between the N-terminal and central mutation regions of cardiac ryanodine receptor.

Authors:  Zheng Liu; Ruiwu Wang; Xixi Tian; Xiaowei Zhong; Jaya Gangopadhyay; Richard Cole; Noriaki Ikemoto; S R Wayne Chen; Terence Wagenknecht
Journal:  J Cell Sci       Date:  2010-04-27       Impact factor: 5.285

Review 6.  Diltiazem. A review of its pharmacological properties and therapeutic efficacy.

Authors:  M Chaffman; R N Brogden
Journal:  Drugs       Date:  1985-05       Impact factor: 9.546

7.  Diltiazem pharmacokinetics in elderly volunteers after single and multiple doses.

Authors:  G Caillé; S Boucher; J Spénard; Z Lakhani; A Russell; J Thiffault; M G Grace
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1991 Jan-Mar       Impact factor: 2.441

Review 8.  Diltiazem. A review of its pharmacology and therapeutic use in older patients.

Authors:  A Markham; R N Brogden
Journal:  Drugs Aging       Date:  1993 Jul-Aug       Impact factor: 3.923

9.  Pharmacokinetics and bioavailability of a sustained-release diltiazem formulation (Mono-Tildiem LP 300 MG) after repeated administration in healthy volunteers.

Authors:  G Bianchetti; C Dubruc; V Sultana; G Houin; P Rosenzweig
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

10.  Improved Predictions of Drug-Drug Interactions Mediated by Time-Dependent Inhibition of CYP3A.

Authors:  Jaydeep Yadav; Ken Korzekwa; Swati Nagar
Journal:  Mol Pharm       Date:  2018-04-10       Impact factor: 4.939

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.